Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 4/20 | 0.37 |
| ▸ | STK4 | Q13043 | 2/20 | 0.35 |
| ▸ | STK3 | Q13188 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492904 | 0.85 | LRRK2 (0.41) | LRRK2IRAK4IRAK1ACVR1KIT | |
| SCHEMBL3492388 | 0.85 | LRRK2 (0.41) | LRRK2IRAK4IRAK1ACVR1KIT | |
| SCHEMBL3491628 | 0.85 | AKT2 (0.43) | LRRK2IRAK4IRAK1KIT | |
| SCHEMBL3490733 | 0.84 | LRRK2 (0.41) | LRRK2IRAK4IRAK1KITSTK4 | |
| SCHEMBL3493290 | 0.84 | KIT (0.45) | LRRK2IRAK4IRAK1KITSTK4 | |
| SCHEMBL3493174 | 0.83 | LRRK2 (0.41) | LRRK2IRAK4IRAK1KITSTK4 | |
| SCHEMBL3492315 | 0.82 | LRRK2 (0.40) | LRRK2IRAK4IRAK1KITSTK4 | |
| SCHEMBL3492317 | 0.82 | LRRK2 (0.40) | LRRK2IRAK4IRAK1KITSTK4 | |
| SCHEMBL3495229 | 0.82 | LRRK2 (0.40) | LRRK2IRAK4IRAK1KITSTK4 | |
| SCHEMBL13343975 | 0.80 | KIT (0.38) | LRRK2IRAK4IRAK1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2125820-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | LRRK2 1684/4885IRAK4 2132/4885IRAK1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.